COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
Preprint
- 22 August 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
As global vaccination campaigns against SARS-CoV-2 proceed, there is particular interest in the longevity of immune protection, especially with regard to increasingly infectious virus variants. Neutralizing antibodies (Nabs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are promising correlates of protective immunity and have been successfully used for prevention and therapy. As SARS-CoV-2 variants of concern (VOCs) are known to affect binding to the ACE2 receptor and by extension neutralizing activity, we developed a bead-based multiplex ACE2-RBD inhibition assay (RBDCoV-ACE2) as a highly scalable, time-, cost-, and material-saving alternative to infectious live-virus neutralization tests. By mimicking the interaction between ACE2 and the RBD, this serological multiplex assay allows the simultaneous analysis of ACE2 binding inhibition to the RBDs of all SARS-CoV-2 VOCs and variants of interest (VOIs) in a single well. Following validation against a classical virus neutralization test and comparison of performance against a commercially available assay, we analyzed 266 serum samples from 168 COVID-19 patients of varying severity. ACE2 binding inhibition was reduced for ten out of eleven variants examined compared to wild-type, especially for those displaying the E484K mutation such as VOCs beta and gamma. ACE2 binding inhibition, while highly individualistic, positively correlated with IgG levels. ACE2 binding inhibition also correlated with disease severity up to WHO grade 7, after which it reduced.Keywords
This publication has 43 references indexed in Scilit:
- Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological ImmunoassayThe Journal of Applied Laboratory Medicine, 2020
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2020
- Neutralizing antibodies for the treatment of COVID-19Nature Biomedical Engineering, 2020
- Correlates of protection against SARS-CoV-2 in rhesus macaquesNature, 2020
- SARS-CoV-2 vaccines in developmentNature, 2020
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCell, 2020
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal modelScience, 2020
- A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2Nature, 2020
- A serological assay to detect SARS-CoV-2 seroconversion in humansNature Medicine, 2020
- Functions of AntibodiesMicrobiology Spectrum, 2014